French Gene Therapy for Wilson’s Disease gets Orphan Status – Labiotech.eu (blog)
Labiotech.eu (blog) |
French Gene Therapy for Wilson’s Disease gets Orphan Status
Labiotech.eu (blog) Vivet Therapeutics has been granted Orphan Drug Designation for its gene therapy for Wilson’s disease, VTX-801, by both the FDA and the European Commission. The French biotech Vivet Therapeutics is developing what could eventually become the first … |
PR Web (press release) |
TeselaGen’s Mike Fero to Speak at SynBioBeta SF 2017
PR Web (press release) TeselaGen founder and CEO Mike Fero has been selected to speak at SynBioBeta SF 2017, the annual conference bringing together entrepreneurs, investors, and practitioners to drive the synthetic biology industry forward. Other speakers at the industry’s … |
Proactive Investors Australia |
Cynata Therapeutics wins US patent for stem cell technology
Proactive Investors Australia Cynata’s new patent covers the proprietary methods relating to the platform’s ability to efficiently manufacture mesenchymal stem cells at scale. The Cymerus process includes donor screening and testing, the induced pluripotent stem cell (iPSC … |
Press Telegraph |
Editas Medicine Receives EMA’s Orphan Medicinal Product …
Nasdaq CAMBRIDGE, Mass., Sept. 26, 2017– Editas Medicine, Inc., a leading genome editing company, today announced the European Medicines Agency granted. Editas Medicine, Inc. (NASDAQ:EDIT) Moving Today – Down $0.85First News 24 |